Sector: Healthcare | Industry: Pharmaceuticals |
Company Contact | |
Address: | 10 Carlson Court, Suite 701 ETOBICOKE ON M9W 6L2 |
Tel: | 1-416-9853647 |
Website: | https://www.hlstherapeutics.com |
IR: | See website |
Key People | ||
Greg Gubitz Chairman of the Board | Craig Stuart Millian Chief Executive Officer, Director | Tim Hendrickson Chief Financial Officer |
Ryan Christopher Lennox Senior Vice President - Human Resources, Legal and Compliance, Company Secretary | David Spence Vice President, Controller | Patricia Perry Vice President of Human Resources |
Jason Gross Vice President - Scientific Affairs | Sanjiv Sharma Chief Commercial Officer |
Business Overview |
HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Insite, MyCare Psychiatry, PERSERIS, Trinomia and Vascepa. Its lead product is Clozaril, which is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Trinomia product related to the treatment of cardiovascular disease. |
Financial Overview |
For the fiscal year ended 31 December 2023, HLS Therapeutics Inc revenues increased 3% to $63.1M. Net loss increased 17% to $27.5M. Revenues reflect Product sales segment increase of 2% to $52.7M, Royalties segment increase of 6% to $10.3M, Canada segment increase of 6% to $39.3M, Rest of the world segment increase of 9% to $5.3M. Higher net loss reflects Derivative financial instruments increase from $2.3M (income) to $1.4M (expense). |
Employees: | 91 as of Mar 13, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $240.76M as of Dec 31, 2023 |
Annual revenue (TTM): | $86.17M as of Dec 31, 2023 |
EBITDA (TTM): | $23.19M as of Dec 31, 2023 |
Net annual income (TTM): | -$37.61M as of Dec 31, 2023 |
Free cash flow (TTM): | $18.04M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $89.71M as of Dec 31, 2023 |
Shares outstanding: | 31,886,247 as of Apr 2, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |